The autocrine role of tryptase in pressure overload-induced mast cell activation, chymase release and cardiac fibrosis

IJC Metabolic and Endocrine

Volumn 10, Issue , 2016, Pages 16-23

  Li, Jianping ^a   Jubair, Shaiban ^a   Levick, Scott P ^b   Janicki, Joseph S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Chymase inhibitor; Hydroxyproline; Protease activated receptor 2; Transverse aortic constriction (TAC); Tryptase inhibitor

Indexed keywords

BUPRENORPHINE; CHYMASE; CHYMOSTATIN; HYDROXYPROLINE; NAFAMSTAT MESILATE; NEDOCROMIL; PROTEINASE ACTIVATED RECEPTOR 2; TRYPTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; DEGRANULATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; MALE; MAST CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESSURE OVERLOAD INDUCED FIBROSIS; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING;

EID: 84959328564     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2015.11.003     Document Type: Article

References (28)

1. Janicki J.S., Brower G.L., Levick S.P. The emerging prominence of the cardiac mast cell as a potent mediator of adverse myocardial remodeling. Methods Mol. Biol. 2015, 1220:121-139.
2. Levick S.P., Meléndez G.C., Plante E., McLarty J.L., Brower G.L., Janicki J.S. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc. Res. 2011, 89:12-19.
3. Zhao X.Y., Zhao L.Y., Zheng Q.S., Su J.L., Guan H., Shang F.J., Niu X.L., He Y.P., Lu X.L. Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol. Cell. Biochem. 2008, 310:159-166.
4. McLarty J.L., Meléndez G.C., Brower G.L., Janicki J.S., Levick S.P. Tryptase/Protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension 2011, 58:264-270.
5. Levick S.P., McLarty J.L., Murray D.B., Freeman R.M., Carver W.E., Brower G.L. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension 2009, 53:1041-1047.
6. Takai S., Jin D., Sakaguchi M., Katayama S., Muramatsu M., Sakaguchi M., Matsumura E., Kim S., Miyazaki M. A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J. Pharmacol. Exp. Ther. 2003, 305:17-23.
7. Matsumoto T., Wada A., Tsutamoto T., Ohnishi M., Isono T., Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003, 107:2555-2558.
8. Liu W., Chen J., Xu T., Tian W., Li Y., Zhang Z., Li W. Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase. Am. J. Hypertens. 2012, 25:250-260.
9. Li J., Jubair S., Janicki J.S. Estrogen inhibits mast cell chymase release to prevent pressure overload-induced adverse cardiac remodeling. Hypertension 2015, 65:328-334.
10. D'andrea M.R., Rogahn C.J., Andrade-Gordon P. Localization of protease-activated receptors -1 and -2 in human mast cells: indications for an amplified mast cell degranulation cascade. Biotech Histochem 2000, 75:85-90.
11. Xia Y., Lee K., Li N., Corbett D., Mendoza L., Frangogiannis N.G. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem. Cell Biol. 2009, 131:471-481.
12. Lu H., Meléndez G.C., Levick S.P., Janicki J.S. Prevention of adverse cardiac remodeling to volume overload in female rats is the result of an estrogen-altered mast cell phenotype. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H811-H817.
13. Sendo T., Itoh Y., Goromaru T., Sumimura T., Saito M., Aki K., Yano T., Oishi R. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. Br. J. Pharmacol. 2003, 138:959-967.
14. Compton S.J., Cairns J.A., Holgate S.T., Walls A.F. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1b and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. J. Immunol. 1998, 161:1939-1946.
15. He S., Gaça M.D., Walls A.F. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase. J Pharmacol Exp Ther 1998, 286:289-297.
16. Sand E., Themner-Persson A., Ekblad E. Mast cells reduce survival of myenteric neurons in culture. Neuropharmacology 2009, 56:522-530.
17. Li J., Lu H., Plante E., Meléndez G.C., Levick S.P., Janicki J.S. Stem cell factor is responsible for the rapid response in mature mast cell density in the acutely stressed heart. J. Mol. Cell. Cardiol. 2012, 53:469-474.
18. Meléndez G.C., McLarty J.L., Levick S.P., Du Y., Janicki J.S., Brower G.L. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010, 56:225-231.
19. Brower G.L., Chancey A.L., Thanigaraj S., Matsubara B.B., Janicki J.S. Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H518-H525.
20. Li W., Guo T., Liang D., Sun Y., Kingery W.S., David Clark J.D. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology 2012, 116:882-895.
21. Castells M., Irani A.A., Schwartz L.B. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J. Immunol. 1987, 138:2184-2189.
22. Akers I.A., Parson M., Hill M.R., Hollenburg M.D., Sanjar S., Laurent G.J., McAnulty R.J. Mast cell tryptase stimulates human lung fibroblast proliferation via protease activate receptor-2. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 278:L193-L201.
23. Sirvent A.E., Gonzalez C., Enriquez R., Fernandez J., Millan I., Barber X., Amoros F. Serum tryptase level and markers of renal dysfunction in a population with chronic kidney disease. J. Nephrol. 2010, 23:282-290.
24. Frungieri M.B., Weidinger S., Meineke V., Kohn F.M., Mayerhofer A. Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPAR_: possible relevance to human fibrotic disorders. Proc Natl Acad Sci US A 2002, 99:15072-15077.
25. Mori S., Itoh Y., Shinohata R., Sendo T., Oishi R., Nishibori M. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J. Pharmacol. Sci. 2003, 92:420-423.
26. He S., Gaca M.D.A., Walls A.F. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase. J Pharmacol Exp Ther 1998, 286:289-297.
27. He S., Aslam A., Gaça M.D., He Y., Buckley M.G., Hollenberg M.D., Walls A.F. Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of proteinase-activated receptor 2 on histamine release. J Pharmacol Exp Ther 2004, 309:119-126.
28. Moormann C., Artuc M., Pohl E., Varga G., Buddenkotte J., Vergnolle N., Brehler R., Henz B.M., Schneider S.W., Luger T.A., Steinhoff M. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J. Invest. Dermatol. 2006, 126:746-755.